Auditory-Nerve 发表于 2025-3-21 17:53:41

书目名称Hematopoietic Growth Factors in Oncology影响因子(影响力)<br>        http://impactfactor.cn/if/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology影响因子(影响力)学科排名<br>        http://impactfactor.cn/ifr/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology网络公开度<br>        http://impactfactor.cn/at/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology网络公开度学科排名<br>        http://impactfactor.cn/atr/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology被引频次<br>        http://impactfactor.cn/tc/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology被引频次学科排名<br>        http://impactfactor.cn/tcr/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology年度引用<br>        http://impactfactor.cn/ii/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology年度引用学科排名<br>        http://impactfactor.cn/iir/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology读者反馈<br>        http://impactfactor.cn/5y/?ISSN=BK0425562<br><br>        <br><br>书目名称Hematopoietic Growth Factors in Oncology读者反馈学科排名<br>        http://impactfactor.cn/5yr/?ISSN=BK0425562<br><br>        <br><br>

争吵 发表于 2025-3-22 00:08:43

Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapyreceiving regimens associated with lower risk should have CSF use guided by individual risk assessment. Critical quality appraisal indicates that the scope and purpose, stakeholder involvement, and applicability of the guidelines differ little. There is more emphasis on comprehensive literature revi

过分自信 发表于 2025-3-22 00:23:53

http://reply.papertrans.cn/43/4256/425562/425562_3.png

bronchiole 发表于 2025-3-22 06:37:01

Ten Years of Meta-analyses on Erythropoiesis-Stimulating Agents in Cancer Patients thrombovascular events. An increased risk of thrombovascular events was observed in all but two meta-analyses (relative risks (RRs) ranging from 1.57 to 1.69). However, potential reporting and publication bias as well as detection bias call for a cautious interpretation of these results. Survival a

ATP861 发表于 2025-3-22 09:41:24

Book 2011in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of

极大痛苦 发表于 2025-3-22 16:35:24

Gary H. Lyman,Nicole M. Kuderere June 1-10, 1987, at the same location. At the plenary session of this meeting it was decided that future meetings should have a principal theme. The theme for the third meeting (June 1- 10, 1989, Kupuri) was Karamata‘s Regular Variation. The principal theme for the fourth meeting (June 1-10, 1990,

Rinne-Test 发表于 2025-3-22 20:50:42

http://reply.papertrans.cn/43/4256/425562/425562_7.png

注意力集中 发表于 2025-3-22 22:49:19

0927-3042 ty of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of 978-1-4614-2728-5978-1-4419-7073-2Series ISSN 0927-3042 Series E-ISSN 2509-8497

易受刺激 发表于 2025-3-23 02:34:44

http://reply.papertrans.cn/43/4256/425562/425562_9.png

值得尊敬 发表于 2025-3-23 08:00:11

Early-Acting Hematopoietic Growth Factors: Biology and Clinical Experiencet biologically interesting molecules and at least theoretically have diverse applications in the evolving field of regenerative medicine. Among this class of regulators, the early-acting hematopoietic growth factors and their cellular targets are perhaps the best characterized and serve as a paradig
页: [1] 2 3 4 5 6
查看完整版本: Titlebook: Hematopoietic Growth Factors in Oncology; Gary H. Lyman,David C. Dale Book 2011 Springer Science+Business Media, LLC 2011 Biology.Molecula